|
|
|
|
|
30.03.26 - 16:30
|
KBRA Assigns Preliminary Rating to FNA 9, LLC (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--#creditratingagency--KBRA assigns a preliminary rating to one class of notes issued by FNA 9, LLC (FNA 9), a $270.0 million property tax lien ABS transaction. FNA 9 represents the Company's seventh public tax lien ABS securitization. Proceeds from the Notes will be used to acquire a portfolio of 9,249 property tax lien assets from municipalities within 13 states, including Texas (53.2%), Florida (19.9%), and New Jersey (8.4%), with a redemptive value of approximately $157.0 million (the Initial Tax Liens) and a weighted average original lien rate of 8.3%.
First National Holdings II, LLC (FNH or the Company) was founded in 2002 and is a specialty finance holding company that purchases real estate tax liens from government entities. FNH is an affiliate of ArrowMark Partners, an asset management company with approximately $24.0 billion assets under management. FNH's current portfolio spans 13 states and totals approximately $500.0 million as of March 2025. FNH is the holding comp...
|
|
|
|
|
|
|
|
|
|
|
03.03.26 - 12:36
|
Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions (Business Wire)
|
|
|
Extension financing adds new investors, Janus Henderson Investors and RA Capital, with strong renewed participation from existing investors
Proceeds will support further clinical development of lead program PHB-050 in food allergy and other atopic conditions
Phase 1 clinical trial for PHB-050 remains on trackCAMBRIDGE, Mass.--(BUSINESS WIRE)--Poplar Therapeutics, Inc., a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions, today announced the closing of its Series A extension round, bringing its total Series A financing to $95 million. The round was led by Janus Henderson Investors, with RA Capital also participating as a new investor. The financing was further supported by existing investors, including SR One, Vida Ventures and affiliates of ArrowMark Partners. The additional capital from this financing will support the continued advancement of its lead asset, PHB-050, through clinical development.
“Poplar Therapeutics is advanc...
|
|
|
19.02.26 - 15:18
|
ArrowMark Financial Corp. (NASDAQ: BANX) Announces the Preliminary Results of its Rights Offering (GlobeNewswire EN)
|
|
|
DENVER, Feb. 19, 2026 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (NASDAQ: BANX) (the “Fund”) announced the preliminary results of its transferable rights offering (the “Offer”). The Offer commenced on January 22, 2026, and expired on February 18, 2026 (the “Expiration Date”). The Offer entitled rights holders to subscribe for up to an aggregate of 2,604,156 of the Fund's shares of common stock, par value $0.001 per share (“Common Shares”). The subscription price was $19.79 per Common Share and was determined based upon 90% of the Fund's net asset value per Common Share at the close of trading on the NASDAQ Global Select Market on the Expiration Date. Common Shares will be issued promptly after receipt of all shareholder payments and completion of the pro-rata allocation of Common Shares in respect of the oversubscription privilege....
|
|
|
|
|
01.02.26 - 21:39
|
XFRA: DIVIDEND/INTEREST INFORMATION - 03.02.2026 - US8617801043 (XETRA)
|
|
|
Das Instrument S9O US8617801043 ARROWMARK FINAN. DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 02.02.2026 und ex Dividende/Zinsen am 03.02.2026
The instrument S9O US8617801043 ARROWMARK FINAN. DL-,001 EQUITY has its pre-dividend/interest day on 02.02.2026 and its ex-dividend/interest day on 03.02.2026...
|
|
|
|
|
|
|
|
|
14.01.26 - 00:18
|
ArrowMark Financial Corp. (NASDAQ: BANX) Announces Terms of Rights Offering (GlobeNewswire EN)
|
|
|
DENVER, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The board of directors (the “Board”) of ArrowMark Financial Corp. (NASDAQ: BANX) (the “Fund”) has approved the terms of the issuance of transferable rights (“Rights”) to the holders of the Fund's shares (the “Common Shareholders”) of common stock, par value $0.001 per share (“Common Shares”), as of the record date, entitling the holders of those Rights to subscribe for Common Shares (the “Offer”). The Board, based on the recommendations and presentations of the Fund's investment adviser, ArrowMark Asset Management, LLC (the “Adviser”), and others, has determined that it is in the best interests of the Fund and the Common Shareholders to conduct the Offer and thereby to increase the assets of the Fund available for investment. In making this determination, the Board considered a number of factors, including potential benefits and costs. In particular, the Board considered the Adviser's belief that the Offer would enable the Fund to ...
|
|
|
|
|
|
|
|
|
19.12.25 - 00:33
|
ArrowMark Financial Corp. Announces $14.9 Million Registered Direct Offering (GlobeNewswire EN)
|
|
|
DENVER, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (Nasdaq: BANX) (“ArrowMark” or the “Fund”) today announced that it has entered into a securities purchase agreement with investors to purchase 673,249 of its shares of common stock, in a registered direct offering. The purchase price for one share of common stock was $22.28. The Net Asset Value at the time of the transaction was $22.20. The registered direct offering is accretive to current shareholders....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
